Literature DB >> 25139778

Treatment of hypertension and metabolic syndrome: lowering blood pressure is not enough for organ protection, new approach-arterial destiffening.

Reuven Zimlichman1.   

Abstract

Cardiovascular risk factors (CVRFs) have been shown to induce end organ damage. Until now, the main approach to reduce CVRF-induced end organ damage was by normalization of CVRFs; this approach was found effective to reduce damage and cardiovascular (CV) events. However, a residual risk always remained even when CVRFs were optimally balanced. An additional risk factor which has an immense effect on the progression of end organ damage is aging. Aging is accompanied by gradual stiffening of the arteries which finally leads to CV events. Until recently, the process of arterial aging was considered as unmodifiable, but this has changed. Arterial stiffening caused by the aging process is similar to the changes seen as a result of CVRF-induced arterial damage. Actually, the presence of CVRFs causes faster arterial stiffening, and the extent of damage is proportional to the severity of the CVRF, the length of its existence, the patient's genetic factors, etc. Conventional treatments of osteoporosis and of hormonal decline at menopause are potential additional approaches to positively affect progression of arterial stiffening. The new approach to further decrease progression of arteriosclerosis, thus preventing events, is the prevention of age-associated arterial structural changes. This approach should further decrease age-associated arterial stiffening. A totally new promising approach is to study the possibility of affecting collagen, elastin, and other components of connective tissue that participate in the process of arterial stiffening. Reduction of pulse pressure by intervention in arterial stiffening process by novel methods as breaking collagen cross-links or preventing their formation is an example of future directions in treatment. This field is of enormous potential that might be revolutionary in inducing further significant reduction of cardiovascular events.

Entities:  

Mesh:

Year:  2014        PMID: 25139778     DOI: 10.1007/s11906-014-0479-z

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  20 in total

1.  Expert consensus document on arterial stiffness: methodological issues and clinical applications.

Authors:  Stephane Laurent; John Cockcroft; Luc Van Bortel; Pierre Boutouyrie; Cristina Giannattasio; Daniel Hayoz; Bruno Pannier; Charalambos Vlachopoulos; Ian Wilkinson; Harry Struijker-Boudier
Journal:  Eur Heart J       Date:  2006-09-25       Impact factor: 29.983

Review 2.  Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention.

Authors:  Peter M Nilsson; Pierre Boutouyrie; Pedro Cunha; Vasilios Kotsis; Krzysztof Narkiewicz; Gianfranco Parati; Ernst Rietzschel; Angelo Scuteri; Stephane Laurent
Journal:  J Hypertens       Date:  2013-08       Impact factor: 4.844

Review 3.  Arterial stiffening: opposing effects of age- and hypertension-associated structural changes.

Authors:  S Laurent; P Lacolley; X Girerd; P Boutouyrie; Y Bezie; M Safar
Journal:  Can J Physiol Pharmacol       Date:  1996-07       Impact factor: 2.273

4.  Hormonal therapy increases arterial compliance in postmenopausal women.

Authors:  C Rajkumar; B A Kingwell; J D Cameron; T Waddell; R Mehra; N Christophidis; P A Komesaroff; B McGrath; G L Jennings; K Sudhir; A M Dart
Journal:  J Am Coll Cardiol       Date:  1997-08       Impact factor: 24.094

Review 5.  Cardiovascular regulatory mechanisms in advanced age.

Authors:  E G Lakatta
Journal:  Physiol Rev       Date:  1993-04       Impact factor: 37.312

6.  Arterial alterations with aging and high blood pressure. A noninvasive study of carotid and femoral arteries.

Authors:  A Benetos; S Laurent; A P Hoeks; P H Boutouyrie; M E Safar
Journal:  Arterioscler Thromb       Date:  1993-01

7.  Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study.

Authors:  Pierre Boutouyrie; Assya Achouba; Patrick Trunet; Stéphane Laurent
Journal:  Hypertension       Date:  2010-04-19       Impact factor: 10.190

8.  Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives.

Authors:  Anne-Isabelle Tropeano; Pierre Boutouyrie; Bruno Pannier; Robinson Joannides; Elisabeth Balkestein; Sandrine Katsahian; Brigitte Laloux; Christian Thuillez; Harry Struijker-Boudier; Stéphane Laurent
Journal:  Hypertension       Date:  2006-05-15       Impact factor: 10.190

9.  Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. Comparison between occidental and Chinese communities.

Authors:  R Virmani; A P Avolio; W J Mergner; M Robinowitz; E E Herderick; J F Cornhill; S Y Guo; T H Liu; D Y Ou; M O'Rourke
Journal:  Am J Pathol       Date:  1991-11       Impact factor: 4.307

Review 10.  Extracellular matrix synthesis in vascular disease: hypertension, and atherosclerosis.

Authors:  Markella Ponticos; Barbara D Smith
Journal:  J Biomed Res       Date:  2013-09-20
View more
  7 in total

1.  Association Between Long-Term Blood Pressure Variability and 10-Year Progression in Arterial Stiffness: The Multiethnic Study of Atherosclerosis.

Authors:  Yacob G Tedla; Yuichiro Yano; Mercedes Carnethon; Philip Greenland
Journal:  Hypertension       Date:  2016-11-14       Impact factor: 10.190

Review 2.  Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Jacob A Udell; Julie A Lovshin; David Z I Cherney
Journal:  Circulation       Date:  2017-10-24       Impact factor: 29.690

Review 3.  Human-induced pluripotent stem cells for modelling metabolic perturbations and impaired bioenergetics underlying cardiomyopathies.

Authors:  Chrishan J A Ramachandra; Jasper Chua; Shuo Cong; Myu Mai Ja Kp; Winston Shim; Joseph C Wu; Derek J Hausenloy
Journal:  Cardiovasc Res       Date:  2021-02-22       Impact factor: 10.787

Review 4.  SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.

Authors:  Silvio E Inzucchi; Bernard Zinman; Christoph Wanner; Roberto Ferrari; David Fitchett; Stefan Hantel; Rosa-Maria Espadero; Hans-Jürgen Woerle; Uli C Broedl; Odd Erik Johansen
Journal:  Diab Vasc Dis Res       Date:  2015-01-14       Impact factor: 3.291

Review 5.  New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon?

Authors:  Ludovit Paulis; Romana Rajkovicova; Fedor Simko
Journal:  Curr Hypertens Rep       Date:  2015-06       Impact factor: 5.369

Review 6.  SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists.

Authors:  Elamin Abdelgadir; Fauzia Rashid; Alaaeldin Bashier; Razan Ali
Journal:  J Clin Med Res       Date:  2018-06-27

7.  Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial.

Authors:  Andrea Natali; Lorenzo Nesti; Iacopo Fabiani; Enrico Calogero; Vitantonio Di Bello
Journal:  Cardiovasc Diabetol       Date:  2017-10-12       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.